Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...
Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...
Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This ...
Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...
Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...
Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and ...
Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team. Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University. Dr. Cooper has been a valuable resource in Halberd’s work at ...
Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown ...
Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to ...
Tau buildup in the brain is linked to Alzheimer’s and other neurodegenerative diseases. Jackson Center, PA, February 8, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process. Excess Tau in CSF ...